Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/ICU 37% Improvement Relative Risk c19early.org/d Giannini et al. Vitamin D for COVID-19 LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? Retrospective 91 patients in Italy Lower death/ICU with vitamin D (not stat. sig., p=0.13) Giannini et al., Nutrients, doi:10.3390/nu13010219 Favors vitamin D Favors control
Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study
Giannini et al., Nutrients, doi:10.3390/nu13010219
Giannini et al., Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A.., Nutrients, doi:10.3390/nu13010219
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 91 hospitalized patients, 36 treated with high-dose cholecalciferol, showing lower combined death/ICU admission with treatment.
Authors also analyze the relationship with comorbidity burden, finding that the positive effect of high-dose cholecalciferol on the combined endpoint was significantly amplified with increasing comorbidity burden.
risk of death/ICU, 36.6% lower, RR 0.63, p = 0.13, treatment 14 of 36 (38.9%), control 29 of 55 (52.7%), NNT 7.2, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Giannini et al., 14 Jan 2021, retrospective, Italy, peer-reviewed, 21 authors, dosage 200,000IU days 1-2.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study Sandro Giannini 1, * , Giovanni Passeri 2 , Giovanni Tripepi 3 , Stefania Sella 1 , Maria Fusaro 1,4 , Gaetano Arcidiacono 1 , Marco Onofrio Torres 1 , Alberto Michielin 1 , Tancredi Prandini 1 , Valeria Baffa 1 , Andrea Aghi 1 , Colin Gerard Egan 5 , Martina Brigo 6 , Martina Zaninotto 7 , Mario Plebani 7 , Roberto Vettor 8 , Paola Fioretto 8 , Maurizio Rossini 9 , Alessandro Vignali 2 , Fabrizio Fabris 1 and Francesco Bertoldo 6 1 2 3 4 5 6   Citation: Giannini, S.; Passeri, G.; 7 8 Tripepi, G.; Sella, S.; Fusaro, M.; Arcidiacono, G.; Torres, M.O.; 9 Michielin, A.; Prandini, T.; Baffa, V.; et al. Effectiveness of In-Hospital * Clinica Medica 1, Department of Medicine, University of Padova, 35128 Padova, Italy; stefania.sella@unipd.it (S.S.); dante.lucia11@gmail.com (M.F.); gparcidiacono91@gmail.com (G.A.); marcoonofrio.torres@studenti.unipd.it (M.O.T.); alberto.michielin89@gmail.com (A.M.); tancredi.prandini@gmail.com (T.P.); valeria.baffa@gmail.com (V.B.); andrea.aghi@gmail.com (A.A.); fabrizio.fabris@unipd.it (F.F.) Unit of Clinica e Terapia Medica, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy; giovanni.passeri@unipr.it (G.P.); alessandro.vignali@gmail.com (A.V.) National Research Council (CNR), Institute of Clinical Physiology (IFC), Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, 89124 Reggio Calabria, Italy; gtripepi@ifc.cnr.it National Research Council (CNR), Institute of Clinical Physiology (IFC), 56124 Pisa, Italy CE Medical Writing, 56021 Pisa, Italy; colingegan@gmail.com Internal Medicine, Department of Medicine, University Hospital AOUI, 37134 Verona, Italy; martina.brigo@gmail.com (M.B.); francesco.bertoldo@univr.it (F.B.) Laboratory Medicine Unit, Department of Medicine, University of Padova, 35128 Padova, Italy; marti.zaninotto@libero.it (M.Z.); mario.plebani@unipd.it (M.P.) Clinica Medica 3, Department of Medicine, University of Padova, 35128 Padova, Italy; roberto.vettor@unipd.it (R.V.); paola.fioretto@unipd.it (P.F.) Rheumatology Unit, Department of Medicine, University of Verona, 37134 Verona, Italy; maurizio.rossini@univr.it Correspondence: sandro.giannini@unipd.it; Tel.: +39-049-8212169 Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study. Nutrients 2021, 13, 219. https://doi.org/10.3390/nu13010219 Received: 16 December 2020 Accepted: 11 January 2021 Published: 14 January 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ Abstract: Little information is available on the beneficial effects of cholecalciferol treatment in comorbid patients hospitalized for COVID-19. The aim of this study was to retrospectively examine the clinical outcome of patients receiving in-hospital high-dose bolus cholecalciferol. Patients with a positive diagnosis of SARS-CoV-2 and overt COVID-19, hospitalized from 15 March to 20 April 2020, were considered. Based on clinical characteristics, they were supplemented (or not) with 400,000..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit